Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.10 USD
Change Today -0.01 / -0.90%
Volume 387.2K
As of 4:30 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (ATHX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/23/15 - $3.43
52 Week Low
04/17/15 - $0.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ATHERSYS INC (ATHX)

Related News

No related news articles were found.

athersys inc (ATHX) Related Businessweek News

No Related Businessweek News Found

athersys inc (ATHX) Details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has completed Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-versus-host disease. It is also developing MultiStem cell therapy for the treatment of acute respiratory distress syndrome. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. In addition, the company is involved in identifying and developing small molecule compounds with potential applications in indications, including obesity; related metabolic conditions, such as diabetes; and neurological indications consisting of schizophrenia. It has license agreement with Chugai Pharmaceutical Co., Ltd. to develop MultiStem cell therapy for ischemic stroke in Japan, as well as collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; and collaboration with Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets produced compound screening and development. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

57 Employees
Last Reported Date: 03/12/15
Founded in 1995

athersys inc (ATHX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $599.8K
President, Chief Operating Officer and Secret...
Total Annual Compensation: $464.5K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $462.0K
Principal Financial Officer and Vice Presiden...
Total Annual Compensation: $283.3K
Executive Vice President of Regenerative Medi...
Total Annual Compensation: $381.6K
Compensation as of Fiscal Year 2014.

athersys inc (ATHX) Key Developments

Athersys, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Athersys, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were $731,000 compared to $707,000 a year ago. Loss from operations was $6,893,000, compared to $7,389,000 a year ago. Net loss and comprehensive loss was $12,482,000 compared to $11,484,000 a year ago. The increase in net loss reflects a $496,000 reduction in loss from operations as offset by the impact of the $1.5 million increase in expense from the change in fair value of warrant liabilities. Basic and diluted net loss per common share was $0.16 against $0.15 a year ago. The net loss includes a non-cash expense of $5.6 million related to the change in fair value of warrant liabilities and $0.8 million related to stock-based compensation, working out to $0.08 a share. Excluding the items, the company would have reported a loss of $0.08. Cash provided by operating activities was $1.1 million compared to cash used by operating activities of $7.3 million in the first quarter of 2014.

Athersys, Inc., Annual General Meeting, Jun 24, 2015

Athersys, Inc., Annual General Meeting, Jun 24, 2015., at 08:00 US Eastern Standard Time. Location: Marriott Hotel at Key Center. Agenda: To consider the election of seven Directors nominated by the Board of Directors; to consider and ratify the appointment of Ernst & Young LLP as Athersys, Inc.’s independent auditors for the fiscal year ending December 31, 2015; and approve, on an advisory basis, named executive officer compensation.

Athersys, Inc. - Special Call

To present the recently announced interim results of its exploratory Phase 2 clinical study of the intravenous administration of MultiStem cell therapy to treat patients who have suffered an ischemic stroke


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATHX:US $1.10 USD -0.01

ATHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $9.99 USD -0.01
Caladrius Biosciences Inc $1.74 USD -0.05
Cytori Therapeutics Inc $0.44 USD 0.00
IntelliCell BioSciences Inc $0.0001 USD 0.00
StemCells Inc $0.42 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ATHX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 53.4x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at